Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with Chronic Kidney Disease (CKD) has been on hemodialysis 3 times per week~* Patient receiving treatment for itch~* Patient has a baseline NRS score \> 4~Exclusion Criteria:~* Patient has pruritus cause other than CKD or its complications~* Patients has hepatic cirrhosis~* Patient has a known history of allergic reaction to opiates

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MR13A9/MR13A9 (Type: EXPERIMENTAL): Patients are administered MR13A9 for 6 weeks (double-blind period), followed by MR13A9 for 52 weeks (open-label period).
- Placebo/MR13A9 (Type: PLACEBO_COMPARATOR): Patients are administered Placebo for 6 weeks (double-blind period), followed by MR13A9 for 52 weeks (open-label period).

Based on this trial design, predict the completion outcome and termination type (if applicable).